Related Experiment Video

Updated: May 12, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Flavia Pichiorri1, Dario Palmieri, Luciana De Luca

  • 1Division of Hematology, College of Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. flavia.pichiorri@osumc.edu

The Journal of Experimental Medicine
|April 24, 2013
PubMed

Insights

Nucleolin (NCL) regulates microRNAs (miRNAs) crucial for breast cancer. Targeting NCL with aptamers reduces these miRNAs, inhibiting cancer cell aggressiveness and offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) play a significant role in human cancers, but therapeutic modulation of their levels remains challenging.
  • Nucleolin (NCL), a key nucleolar protein, has been implicated in various cellular processes.

Purpose of the Study:

  • To investigate the role of nucleolin (NCL) in regulating microRNA (miRNA) expression in breast cancer.
  • To explore the therapeutic potential of targeting NCL for breast cancer treatment.

Main Methods:

  • Analysis of NCL's posttranscriptional regulation of specific miRNAs (miR-21, miR-221, miR-222, miR-103) involved in breast cancer.
  • Assessment of NCL and NCL-dependent miRNA expression in human breast tumors.
  • Inhibition of NCL using guanosine-rich aptamers in vitro and in vivo models.

Main Results:

  • NCL was found to posttranscriptionally regulate key breast cancer-associated miRNAs.
  • NCL is overexpressed in breast tumors, correlating with NCL-dependent miRNA levels.
  • NCL inhibition via aptamers decreased NCL-dependent miRNAs and their targets, reducing cancer cell aggressiveness.

Conclusions:

  • NCL is a critical regulator of specific oncogenic miRNAs in breast cancer.
  • NCL-targeting aptamers represent a promising therapeutic strategy for modulating miRNA expression in breast cancer treatment.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...